Add time:09/03/2019         Source:sciencedirect.com

Biguanide (CAS#56-03-01) is a parent compound that is used to synthesize drugs for controlling noninsulin-dependent diabetes mellitus (Type II), or NIDDM. Three clinically important biguanides that were released into the market are buformin, phenformin, and metformin. Phenformin was withdrawn from the market in 1970s, but buformin is still in use in certain countries except United States. In the last decade, metformin (1,1-dimethylbiguanide hydrochloride) turned out to be a frontrunner among all diabetic medications. Metformin (CAS# 657-24-9) came into use in the United States in 1995, and is sold as Glucophage®. It is the first-line drug of choice for the treatment of NIDDM, particularly in overweight and obese individuals, and those with normal kidney function. As of 2010, metformin is one of only two oral antidiabetics in the World Health Organization model list of essential medicines, the other being glibenclamide. The major problem with metformin has been induction of lactic acidosis or hepatotoxicity in less than 1% of patients. It acts as an insulin sensitizing agent, probably through activation of adenosine monophosphate–dependent kinase in liver and muscle tissue. Biguanide drugs are advantageous because they do not enhance insulin release like the sulfonylureas; therefore, disorders of glucose homeostasis are rare with metformin. Intentional or suicidal overdoses with metformin are relatively uncommon, but may have serious consequences; these are often linked to concurrent use of other antidiabetic medications. Likewise, metformin-induced hyperglycemic toxicity is even rarer, and has largely been ascribed to the patients' preexisting conditions such as acute pancreatitis. Review of Medline revealed a plethora of research publications vouching for an emerging anticancer role for metformin.

We also recommend Trading Suppliers and Manufacturers of POLYAMINOPROPYL BIGUANIDE (cas 133029-32-0). Pls Click Website Link as below: cas 133029-32-0 suppliers